Fusion Pharmaceuticals Future Growth
Future criteria checks 2/6
Fusion Pharmaceuticals's earnings are forecast to decline at 7.9% per annum while its annual revenue is expected to grow at 56.7% per year. EPS is expected to decline by 0.6% per annum. Return on equity is forecast to be -187.6% in 3 years.
Key information
-7.9%
Earnings growth rate
-0.6%
EPS growth rate
| Biotechs earnings growth | 20.7% |
| Revenue growth rate | 56.7% |
| Future return on equity | -187.6% |
| Analyst coverage | Good |
| Last updated | 11 Apr 2024 |
Recent future growth updates
Recent updates
Fusion Pharmaceuticals' Partnerships Strengthen Long-Term Outlook
Mar 03Health Check: How Prudently Does Fusion Pharmaceuticals (NASDAQ:FUSN) Use Debt?
Jan 30
Fusion Pharmaceuticals initiated at buy at Truist on lead candidate for solid tumors
Sep 16Fusion Pharma doses first patient in phase 1/2 study for solid tumors treatment
Aug 29Will Fusion Pharmaceuticals (NASDAQ:FUSN) Spend Its Cash Wisely?
Aug 10Fusion Pharmaceuticals GAAP EPS of -$0.44 beats by $0.09, revenue of $0.57M beats by $0.46M
Aug 09Fusion Pharma wins FDA nod to start trials for solid tumor candidate
Jun 23We're Not Very Worried About Fusion Pharmaceuticals' (NASDAQ:FUSN) Cash Burn Rate
Jan 16We're Not Very Worried About Fusion Pharmaceuticals' (NASDAQ:FUSN) Cash Burn Rate
Aug 28Fusion Pharma trades higher on early-stage data for cancer therapy
Jun 14We're Hopeful That Fusion Pharmaceuticals (NASDAQ:FUSN) Will Use Its Cash Wisely
Apr 05How Much Of Fusion Pharmaceuticals Inc. (NASDAQ:FUSN) Do Institutions Own?
Mar 01Who Has Been Buying Fusion Pharmaceuticals Inc. (NASDAQ:FUSN) Shares?
Jan 25Here's Why We're Not Too Worried About Fusion Pharmaceuticals' (NASDAQ:FUSN) Cash Burn Situation
Dec 21Fusion Pharmaceuticals EPS misses by $0.04
Nov 10Fusion Pharma teams up with AstraZeneca in next-gen radiopharmaceuticals for cancer
Nov 02Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | 6 | -162 | -141 | -123 | 9 |
| 12/31/2025 | 1 | -139 | -121 | -106 | 9 |
| 12/31/2024 | 1 | -115 | -101 | -90 | 11 |
| 12/31/2023 | 2 | -95 | -86 | -82 | N/A |
| 9/30/2023 | 2 | -91 | -87 | -83 | N/A |
| 6/30/2023 | 0 | -98 | -89 | -86 | N/A |
| 3/31/2023 | 1 | -92 | -87 | -84 | N/A |
| 12/31/2022 | 1 | -88 | -75 | -73 | N/A |
| 9/30/2022 | 2 | -80 | -72 | -70 | N/A |
| 6/30/2022 | 2 | -76 | -72 | -70 | N/A |
| 3/31/2022 | 2 | -83 | -72 | -70 | N/A |
| 12/31/2021 | 1 | -81 | -77 | -76 | N/A |
| 9/30/2021 | 1 | -77 | -64 | -62 | N/A |
| 6/30/2021 | 1 | -68 | -55 | -54 | N/A |
| 3/31/2021 | N/A | -86 | -44 | -43 | N/A |
| 12/31/2020 | N/A | -80 | -31 | -30 | N/A |
| 9/30/2020 | N/A | -75 | -32 | -31 | N/A |
| 6/30/2020 | N/A | -65 | -21 | -21 | N/A |
| 3/31/2020 | N/A | -24 | -19 | -18 | N/A |
| 12/31/2019 | N/A | -16 | -14 | -14 | N/A |
| 12/31/2018 | N/A | -12 | -11 | -10 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: FUSN is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: FUSN is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: FUSN is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: FUSN's revenue (56.7% per year) is forecast to grow faster than the US market (8.1% per year).
High Growth Revenue: FUSN's revenue (56.7% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: FUSN is forecast to be unprofitable in 3 years.